Product category:
Chemicals and biochemicals
News Release from: Perkin Elmer LAS (UK)
Edited by the Laboratorytalk Editorial
Team on 19 November 2002
Supplying labelled nucleotides to New
York
International centre for biomedical research and technology and affiliated institutions chose supplier of non-radioactive-labelled nucleotides
PerkinElmer Life and Analytical Sciences has announced it has been selected by Amdec Foundation to supply key non-radioactive-labelled nucleotides for its affiliated institutions at a significant saving Amdec was developed by leaders in New York's medical and scientific community to establish New York as the international centre for biomedical research and technology over the next decade
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
Through Amdec, its 39 affiliated institutions are working collaboratively to develop large-scale basic science and clinical research projects, expand New York's research infrastructure, recruit talented researchers to New York's scientific institutions, and pursue research-related business opportunities.
This agreement with PerkinElmer represents Amdec's first agreement pertaining to microarray reagents, and continues Amdec's mission to develop business relationships that foster more cost-effective research.
"One of the major goals of Amdec is the standardisation of operating procedures among the member institutions.
Our agreement with PerkinElmer will provide Amdec members easier access and better pricing on some of the most critical components needed for our microarray-based research," said Maria K Mitchell, president of Amdec.
"PerkinElmer's long standing reputation in the area of quality labelled nucleotides was one of the major reasons for establishing this agreement, which will ultimately help Amdec realise its objectives," said Andrew Brooks, director of the Functional Genomics Center at the University of Rochester Medical Center, who leads Amdec's microarray resource initiative.
"This opportunity to work with Amdec represents an unprecedented relationship, allowing PerkinElmer to play a pivotal role in assisting the New York health and sciences community in standardising their microarray protocols," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"This agreement further demonstrates our commitment to providing quality products and services to organisations looking to enhance their research programmes." PerkinElmer will offer Amdec affiliated-institutions its proprietary nucleotide analogues, including array-certified cyanine- and biotin-labelled nucleotides.
These products enable rapid, simultaneous screening of many genes.
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
